CRP and chronic kidney disease: The antibody, ziltivekimab, has so far been effective at reducing CRP levels in patients with chronic kidney disease, who are at increased risk of developing CVD and are contraindicated for alternative therapies such as colchicine (Ridker et al., 2021).